These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 22133052)

  • 21. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
    Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
    Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry.
    Harrold LR; Reed GW; Shewade A; Magner R; Saunders KC; John A; Kremer JM; Greenberg JD
    J Rheumatol; 2015 Jul; 42(7):1090-8. PubMed ID: 25934829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.
    Chatzidionysiou K; van Vollenhoven RF
    Scand J Rheumatol; 2013; 42(3):190-5. PubMed ID: 23286833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
    Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
    Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
    Fabris M; Quartuccio L; Vital E; Pontarini E; Salvin S; Fabro C; Zabotti A; Benucci M; Manfredi M; Ravagnani V; Biasi D; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Bazzicchi L; Saracco M; Pellerito R; Cimmino M; Carraro V; Semeraro A; Schiavon F; Caporali R; Bortolotti R; Govoni M; Fogolari F; Tonutti E; Bombardieri S; Emery P; De Vita S
    Arthritis Rheum; 2013 Jan; 65(1):88-97. PubMed ID: 23001900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment.
    Di Muzio G; Perricone C; Ballanti E; Kroegler B; Greco E; Novelli L; Conigliaro P; Cipriani P; Giacomelli R; Perricone R
    Int J Immunopathol Pharmacol; 2011; 24(2):357-66. PubMed ID: 21658310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
    Finckh A; Ciurea A; Brulhart L; Möller B; Walker UA; Courvoisier D; Kyburz D; Dudler J; Gabay C;
    Ann Rheum Dis; 2010 Feb; 69(2):387-93. PubMed ID: 19416802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
    Karlsson JA; Kristensen LE; Kapetanovic MC; Gülfe A; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):507-13. PubMed ID: 18304941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of rituximab in rheumatoid arthritis: about 55 patients].
    Abourazzak FE; Soubai RB; Chellat H; El Mezouar I; Harzy T
    Rev Med Brux; 2015; 36(3):133-8. PubMed ID: 26372973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.
    Chatzidionysiou K; Lukina G; Gabay C; Hetland ML; Hauge EM; Pavelka K; Nordström D; Canhão H; Tomsic M; Rotar Z; Lie E; Kvien TK; van Vollenhoven RF; Saevarsdottir S
    Scand J Rheumatol; 2019 Jan; 48(1):17-23. PubMed ID: 30260261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.